ASCO 2024: Belzutifan in Patients with Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 2 LITESPARK-013 Study

ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

Related Keywords

United States ,Toronto ,Ontario ,Canada ,Washington ,Georgetown University ,District Of Columbia ,Chicago ,Illinois ,American ,Michael Atkins ,Michaelb Atkins ,University Of Toronto ,Georgetown Lombardi Comprehensive Cancer Center ,Department Of Medical Oncology ,Database Consortium ,Twitter ,Georgetown University Medical Center ,Merck Sharp Dome ,Society Of Urologic Oncology ,International Metastatic ,American Society Of Clinical Oncology ,Clinical Oncology ,Annual Meeting ,Deputy Director ,Scholl Professor ,Vice Chair ,Medical Oncology ,Rashid Sayyid ,Urologic Oncology ,Clinical Fellow ,